All In Biotech

Drug Trial Radar · NCT00089791

A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis

A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months)

Last checked: Nov 20, 2026Latest source record: Nov 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 7,808 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

7,808

Actual

Start

Aug 1, 2004

Primary completion

Jun 17, 2008

Study completion Jun 17, 2008

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Aug 16, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Female only, from 60 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the effectiveness and safety of denosumab in treating women with Postmenopausal Osteoporosis.

Conditions

  • Osteoporosis

Interventions

  • placeboDrug

    Placebo administered by subcutaneous injection

  • DenosumabDrug

    Denosumab 60 mg administered by subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With New Vertebral FracturesTime frame: 36 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.